Innovating Tau-Targeted Preclinical Models to Strengthen Translation in Alzheimer’s Drug Discovery
- Developing advanced cell-based tau models to more accurately capture disease-relevant biology, enhancing translational reliability before clinical entry
- Screening novel therapeutic approaches in tau-focused systems to identify mechanisms that directly impact aggregation and pathology, reducing late-stage trial failure
- Aligning preclinical tau biomarkers with clinical endpoints to build stronger continuity across the R&D pipeline, de-risking candidate progression